Budesonide for swallowing problems in people with dystrophic epidermolysis bullosa
Looks back at budesonide use for swallowing difficulty in dystrophic epidermolysis bullosa.
Key facts
- Who runs it
- Centre Hospitalier Universitaire de Nice
- Where
- France3 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Treatment of Dysphagia in Patients With Dystrophic Epidermolysis Bullosa With Budesonide: a Retrospective Bicentric Study Nice - Paris St Louis / Necker (EBUDE Study)
- Status
- Not yet recruiting
- People taking part
- 15 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional
- Treatments tested
- The retrospective data collected will be entered into an eCRF and then analyzed centrally
- Record updated
- 6 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with dystrophic epidermolysis bullosa (EBD) who had budesonide for swallowing difficulty. It reviews their past medical files.
- Age
- Any age, from 1 Year.
- Sex
- All sexes.
- Disease stage
- EBD in dominant or recessive form, with swallowing difficulty (dysphagia) that did not improve with usual treatments. The clinical form must be described in the file.
- Earlier treatment
- Must have been treated with budesonide for at least one month. The patient must have rated the benefit of treatment at 1 and/or 3 months.
Main reasons for not taking part
- No precise clinical or biological diagnosis
- Budesonide treatment for less than 1 month
- No assessment data in the medical file
- Objection to the use of their data
- Not covered by social security
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients of both sexes, of any age, with EBD in dominant or recessive form, treated for at least one month with budesonide for dysphagia resistant to usual treatments
- A description of the clinical form must be available in the file. The patient must assess the benefit of treatment at 1 and/or 3 months of Budesonide
- Patients must be affiliated with social security. For adults, consent of non-opposition is required, and for minors, non-opposition from one of the parents or the person holding parental authority must be collected
Who cannot take part
- No precise clinical or biological diagnosis. Treatment with Budesonide < 1 month. No evaluation criteria in the file / Objection to the use of data (withdrawal of non-opposition)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Budesonide is an anti-inflammatory medication that works by decreasing the immune system's overreaction. In the treatment of eosinophilic esophagitis, especially with Jorveza or a preparation made in a pharmacy, it reduces the production of substances responsible for inflammation in the esophagus. This action reduces the accumulation of certain inflammatory cells (eosinophils) and thus improves the symptoms and lesions of the esophagus.
Read full original descriptionShow less
Dystrophic epidermolysis bullosa (EBD) is a rare genetic disease that makes the skin and mucous membranes very fragile. Blisters, sores and wounds can appear as a result of even minor trauma. Scarring is often abnormal and can cause tissue to shrink or shrink.
To date, only two studies involving a total of eight children with EBD have evaluated a budesonide-based preparation. The results show an improvement in swallowing difficulties (dysphagia) as well as good tolerance of the treatment. However, there are currently no published data regarding the use of Jorveza in the form of an orally disintegrating tablet in adults with EBD.
Through the follow-up of patients treated at the MAGEC reference center, specialized in rare genetic diseases of the skin and mucous membranes, we aim to evaluate the interest and effects of budesonide treatment in individuals with EBD presenting with dysphagia.
The group in the trial
- recessive dystrophic epidermolysis bullosa with dysphagia treated with oral BUDESONIDEOther group
The retrospective data collected will be entered into an eCRF and then analyzed centrally
Treatment: The retrospective data collected will be entered into an eCRF and then analyzed centrally
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Treatment of Dysphagia in Patients With Dystrophic Epidermolysis Bullosa With Budesonide: a Retrospective Bicentric Study Nice - Paris St Louis / Necker (EBUDE Study)
- Plain-language title
- Budesonide for swallowing problems in people with dystrophic epidermolysis bullosaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 6 July 2026